Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 3,9814,000 of 20,252 grants

Active OTHER RESEARCH-RELATED
Admin Core
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Summary The primary goal of the Administrative Core is to provide logistical, organizational, and managerial support for this Biomarker Characterization Center (BCC) and foster the...

Active OTHER RESEARCH-RELATED
Understanding Breast Cancer Risk and Screening in Transgender Persons through a Pilot Breast Cancer Screening Program
NATIONAL CANCER INSTITUTE Medical College of Wisconsin United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT In the U.S., an estimated 1.4 million people identify as transgender (TG), defined as a person whose gender is different than their sex assigned at birth,...

$2.1M
USD
Active OTHER RESEARCH-RELATED
BCC for Prostate Cancer: Discovery and Translation of Biomarkers for Clinical Unmet Needs
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Active surveillance (AS) is the preferred management option for low risk prostate cancer (PCa) patients who would benefit from conservative treatment. However, due to the lack of r...

$9.36M
USD
Active OTHER RESEARCH-RELATED
Admin Core
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Summary The primary goal of the Administrative Core is to provide logistical, organizational, and managerial support for this Biomarker Characterization Center (BCC) and foster the...

Active OTHER RESEARCH-RELATED
Biomarker Development Laboratory
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Active surveillance (AS), which holds off on treatment for low-risk PCa patients until signs of progression are detected through careful monitoring, was developed as a potential so...

Active OTHER RESEARCH-RELATED
Biomarker Reference Laboratory
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Our proposed EDRN BRL, which is located within the Clinical Chemistry Division (CCD) of the Johns Hopkins Medical Institutions, will be an integral part of the BCC. The BRL will co...

Active NON-SBIR/STTR RPGS
The Role of IL-15 in Cutaneous T-cell Lymphoma Progression
NATIONAL CANCER INSTITUTE Thomas Jefferson University United States 2023 – 2028

PROJECT SUMMARY Cutaneous T-cell Lymphoma (CTCL) is an incurable disease characterized by the localization of neoplastic T lymphocytes to the skin. Patients display a progressive d...

$3.57M
USD
Completed NON-SBIR/STTR RPGS
A Novel Framework for Sensitive and Reliable Early Diagnosis, Topographic Mapping, and Stiffness Classification of Colorectal Cancer Polyps
NATIONAL CANCER INSTITUTE University of Texas At Austin United States 2023 – 2025

Summary/Abstract: Our long-term goal is to develop a novel soft robotic endoscope with intelligent tactile sensing balloons and complementary machine learning (ML) and computer vis...

$1.79M
USD
Active OTHER RESEARCH-RELATED
Biomarker Development Laboratory
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Active surveillance (AS), which holds off on treatment for low-risk PCa patients until signs of progression are detected through careful monitoring, was developed as a potential so...

Active OTHER RESEARCH-RELATED
Biomarker Reference Laboratory
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2028

Our proposed EDRN BRL, which is located within the Clinical Chemistry Division (CCD) of the Johns Hopkins Medical Institutions, will be an integral part of the BCC. The BRL will co...

Active NON-SBIR/STTR RPGS
The Role of IL-15 in Cutaneous T-cell Lymphoma Progression
NATIONAL CANCER INSTITUTE Thomas Jefferson University United States 2023 – 2028

PROJECT SUMMARY Cutaneous T-cell Lymphoma (CTCL) is an incurable disease characterized by the localization of neoplastic T lymphocytes to the skin. Patients display a progressive d...

$3.39M
USD
Active OTHER RESEARCH-RELATED
Understanding Breast Cancer Risk and Screening in Transgender Persons through a Pilot Breast Cancer Screening Program
NATIONAL CANCER INSTITUTE Medical College of Wisconsin United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT In the U.S., an estimated 1.4 million people identify as transgender (TG), defined as a person whose gender is different than their sex assigned at birth,...

$2.1M
USD
Completed NON-SBIR/STTR RPGS
A Novel Framework for Sensitive and Reliable Early Diagnosis, Topographic Mapping, and Stiffness Classification of Colorectal Cancer Polyps
NATIONAL CANCER INSTITUTE University of Texas At Austin United States 2023 – 2025

Summary/Abstract: Our long-term goal is to develop a novel soft robotic endoscope with intelligent tactile sensing balloons and complementary machine learning (ML) and computer vis...

$2.11M
USD
Active NON-SBIR/STTR RPGS
Targeting GSK3B in refractory B-cell malignancies
NATIONAL CANCER INSTITUTE Yale University United States 2023 – 2028

Abstract GSK3E functions as essential negative regulator of E-catenin, while E-catenin accumulation represents a central oncogenic driver in cancer. In solid tumors, E-catenin form...

$6.1M
USD
Active NON-SBIR/STTR RPGS
Analyzing Patient-Level Data in a Breast Cancer Clinical Trial
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2023 – 2028

ABSTRACT Most women treated for breast cancer will experience some form of drug-related toxicity and subsequent impairments in Health-related Quality of Life (HRQOL), yet toxicity...

$3.69M
USD
Active RESEARCH CENTERS
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
NATIONAL CANCER INSTITUTE Virginia Commonwealth University United States 2023 – 2028

Project Summary/Abstract Breast cancer is diagnosed in 1-of-8 women and is the most common type of cancer diagnosed at VCU. There are several genetically distinct subtypes of human...

Active NON-SBIR/STTR RPGS
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2023 – 2028

PROJECT SUMMARY There has been little or no long-term improvement in outcomes for patients with treatment-refractory acute myeloid leukemia (AML). The recently developed image-guid...

$7.11M
USD
Completed NON-SBIR/STTR RPGS
Noninvasive monitoring of therapeutic response to immune checkpoint inhibitors using circulating exosomes in non-small cell lung cancer
NATIONAL CANCER INSTITUTE University of Miami School of Medicine United States 2023 – 2025

Summary/ Abstract: The emergence of immune checkpoint blockade (ICB) therapy has revolutionized the treatment for advanced cancers including lung cancer. Particularly, anti-PD-1/PD...

$2.05M
USD
Active RESEARCH CENTERS
United for Health Equity - Living PDX Program (U4HELPP)
NATIONAL CANCER INSTITUTE Virginia Commonwealth University United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT – OVERALL The United for Health Equity-Living PDX Program (U4HELPP) seeks to develop >500 new patient-derived xenograft (PDX) models of cancers originat...

$9.6M
USD
Active RESEARCH CENTERS
Bioinformatics Core
NATIONAL CANCER INSTITUTE Virginia Commonwealth University United States 2023 – 2028

Project Summary/Abstract The primary goal of the Bioinformatics Core of VCU’s U4HELPP is to provide data management, quality control, reproducible analyses, data storage, and data...